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Mucosal vaccination with a live 
recombinant rhinovirus followed 
by intradermal DNA administration 
elicits potent and protective HIV-
specific immune responses
Khamis Tomusange1, Danushka Wijesundara1, Jason Gummow1, Steve Wesselingh2, 
Andreas Suhrbier3, Eric J. Gowans1,* & Branka Grubor-Bauk1,*
Mucosal immunity is deemed crucial to control sexual transmission of human immunodeficiency 
virus (HIV). Herein we report the efficacy of a mucosal HIV vaccine strategy comprising intranasal 
(IN) vaccination with a cocktail of live recombinant human rhinoviruses (HRVs) encoding overlapping 
fragments of HIV Gag and full length Tat (rHRV-Gag/Tat) followed by intradermal (ID) vaccination with 
DNA vaccines encoding HIV Gag and Tat (pVAX-Gag-Tat). This heterologous prime-boost strategy will be 
referred to hereafter as rHRV-DNA. As a control, IN vaccination with wild type (wt)-HRV-A1 followed by 
a single ID dose of pVAX (wt-HRV-A1/pVAX vaccination) was included. rHRV-DNA vaccination elicited 
superior multi-functional CD8+T cell responses in lymphocytes harvested from mesenteric lymph nodes 
and spleens, and higher titres of Tat-specific antibodies in blood and vaginal lavages, and reduced the 
viral load more effectively after challenge with EcoHIV, a murine HIV challenge model, in peritoneal 
macrophages, splenocytes and blood compared compared with wt-HRV-A1/pVAX vaccination or 
administration of 3 ID doses of pVAX-Gag-Tat (3X pVAX-Gag-Tat vaccination). These data provide the 
first evidence that a rHRV-DNA vaccination regimen can induce HIV-specific immune responses in the 
gut, vaginal mucosa and systemically, and supports further testing of this regimen in the development 
of an effective mucosally-targeted HIV-1 vaccine.
A potential reason why previous HIV vaccine trials were ineffective1–3 or modestly effective4 is the failure to 
generate effective mucosal immunity5. A majority of HIV transmissions occur via genito-urinary or genito-rectal 
mucosal surfaces6 and extensive CD4+ T cell depletion occurs in the gastrointestinal mucosa after infection7. This 
highlights the need to develop vaccines capable of eliciting protective HIV-specific immune responses at these 
surfaces. Moreover, previous HIV vaccine strategies focused on systemic vaccination, which induced little or no 
protective immune responses at the mucosa5. Therefore, mucosal vaccination strategies able to elicit HIV-specific 
immunity both systemically and at mucosal surfaces are being actively pursued8.
Ideally, mucosal HIV vaccines should generate broadly neutralizing antibodies (bNAbs) against the envelope 
proteins to prevent primary HIV infection as has been observed in animal studies involving passive transfer of 
broadly neutralizing antibodies9. However, due to the recognised difficulties in designing vaccines capable of 
eliciting Env-specific bNAbs10, a vaccine capable of eliciting high titre anti-Tat NAb might be a feasible alternative 
to controlling HIV replication and delaying disease onset11. An effective HIV vaccine should also induce robust 
poly-functional T cell mediated immunity (CMI) against the relatively conserved Gag proteins, viz. responses 
similar to those seen in long-term non-progressors12,13.
Among the several strategies that have been developed to generate mucosal HIV vaccines is the use of 
mucosally transmitted replication-competent viral vectors14. These vectors usually establish an infection that 
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mimics a natural viral infection, efficiently deliver immunogens to mucosal antigen presenting cells (APCs), 
and facilitate the development of long-lasting humoral and CMI15 without the need for addition of adjuvants14. 
Several replication-competent viral vectors including adenovirus, poliovirus, influenza virus, poxvirus and cyto-
megalovirus vectors have been developed and tested as HIV vaccines, with promising results in large animal 
models14,15, particularly when used in heterologous prime-boost vaccination regimens.
Previously, polioviruses, which are transmitted via mucosal surfaces16, were studied as potential viral vectors 
for HIV vaccine development16,17 and vaccination with a cocktail of live recombinant polioviruses generated pro-
tective immunity against intravaginal challenge with SIVmac251 in 4/7 (57%) vaccinated macaques17. However, 
replication-competent poliovirus vectors have not advanced to human clinical trials mainly due to the high level 
of pre-existing vaccine-induced immunity in the community18 which has been shown to limit the efficacy of 
virus-vectored vaccines1. Like polioviruses, human rhinoviruses (HRVs) are classified in the Picornaviridae and 
share many characteristics, including their genome organisation and mode of transmission19. HRVs are transmit-
ted via the nasal mucosa20 making them potential vaccine vectors to elicit mucosal immunity.
We have previously developed a series of replication-competent, genetically stable recombinant HRV 
serotype-A1 viruses (rHRV-Gag 1–5 and rHRV-Tat) by inserting discrete overlapping fragments of the HIV 
gag gene or the full length tat gene, into the junction of the genes encoding the structural proteins and the 
non-structural proteins (the P1/P2 junction)21. We have now mixed these rHRVs into a single cocktail vaccine 
suitable for intranasal (IN) administration, a route that has been shown to generate pan-mucosal and systemic 
immunity8. Furthermore, IN vaccination is considered to be safe, well tolerated, easily administered and inexpen-
sive8, and consequently, the rHRV-Gag/Tat vaccine represents a potential cost-effective HIV vaccine candidate for 
use in low-income countries. Herein we describe the immune responses against Gag and Tat after vaccination of 
mice IN with rHRV-Gag/Tat followed by ID delivery of DNA encoding Gag and Tat, and evaluate the efficacy of 
this regimen after challenge with ecotropic murine leukaemia HIV (EcoHIV).
Results
rHRV-DNA prime-boost vaccination elicits robust CMI. A robust CMI to HIV Gag appears to corre-
late with control of HIV infection in humans12 and non-human primates22,23. We previously showed that vacci-
nation of mice with 3 doses of pVAX-Gag-PRF elicited broad, poly-functional Gag-specific CMI able to control 
EcoHIV after challenge24, and that vaccination with pVAX-sTat-IMX313 elicited high titre anti-Tat responses 
that also controlled EcoHIV infection post challenge25. Moreover, Tat shows adjuvant activities and the ability to 
broaden CTL responses without affecting Th2 responses when included together Gag- or Env-based HIV vac-
cines26,27. Therefore, we wished to compare the efficacy of rHRV-DNA vaccination with that of wt-HRV-A1/pVAX 
or 3X pVAX-Gag-Tat vaccination. Initially, we used the IFN-γ ELISpot assay (and Gag or Tat peptide pools) to 
compare CMI responses in splenocytes harvested 14 days after the final vaccine inoculation. This experiment 
showed that the Gag-specific responses to the different peptide pools ranged from 169 to 427 and 72 to 278 
(mean SFU/106 cells), in animals vaccinated with rHRV-DNA and 3X pVAX-Gag-Tat, respectively (Fig. 1A–D). 
These responses were detected in splenocytes stimulated with all 5 Gag peptide pools suggesting that each of 
the 5 Gag fragments encoded in the rHRV-Gag/Tat cocktail vaccine was expressed in vivo and thus contrib-
uted to the resultant Gag-specific responses. Splenocytes from the wt-HRV/pVAX vaccination control group 
showed responses which were considerably lower (< 22 mean IFN-γ SFU) than those from unstimulated cells 
from vaccinated mice (mean IFN-γ SFU = 25), thus the net IFN-γ responses in this vaccination group is consid-
ered zero. The combined Gag response was ~2 fold higher after vaccination with rHRV-DNA compared to 3X 
pVAX-Gag-Tatvaccination (1147 and 554, respectively, p = 0.0175) as shown in Fig. 1E. Similarly, wt-HRV/pVAX 
vaccination failed to induce Tat-specific CMI responses above background (mean IFN-γ SFU = 0), but high mag-
nitude Tat-specific CMI responses were readily detected after rHRV-DNA vaccination (mean IFN-γ SFU = 190) 
as shown in Fig. 1F. Furthermore, the Tat-specific CMI responses elicited by rHRV-DNA were ~3.9 fold higher 
than those elicited by 3X pVAX-Gag-Tat (190 compared to 49 SFU, respectively, p = 0.0041) as shown in Fig. 1F.
As IFN-γ ELISpot assays involve extensive in vitro stimulation of effector cells, which can cause 
activation-induced cell death28, splenocytes from immunized mice were stained with the H-2Kd-restricted 
Gag197–205 tetramer to directly enumerate the Gag-specific CD8+ T cells present in vivo. The mean num-
ber of tetramer-positive CD8+ T cells following wt-HRV-pVAX vaccination was less than background from 
unstained cells, thus the net number of tetramer positive cells in this vaccination group is considered zero. 
Moreover, tetramer binding CD8+ T cells (mean of tetramer positive CD8+ T cells = 45921) could be readily 
detected after rHRV-DNA vaccination and these were also significantly higher than those generated follow-
ing 3X pVAX-Gag-Tat vaccination (45921 vs 20814, P = 0.0023) as shown in Fig. 1G. Collectively, these results 
illustrate that rHRV-DNA is more effective at inducing Gag and Tat-specific CMI than wt-HRV-pVAX or 3X 
pVAX-Gag-Tat vaccination.
rHRV-DNA elicits superior systemic poly-functional CMI. T cells capable of producing multiple 
anti-viral cytokines (eg. IFN-γ and TNF-α ) and/or survival/proliferative cytokines (eg. IL-2) i.e. poly-functional 
T cells, are desirable outcomes for HIV-1 vaccine development as the presence of these cells appears to correlate 
with improved control of HIV infection in humans12,29 and SIV infection in non-human primates22,23. The data 
showed that KdGag197–205-specific CD8+ T cells from all rHRV-DNA vaccinated animals responded to vaccination 
by producing IL-2, IFN-γ or TNF-α , whereas responses from wt-HRV-A1/pVAX vaccinated animals did not 
surpass background from unstimulated cells (Fig. 2A–C). Furthermore, the number of CD8+ T cells producing 
IFN-γ , IL-2 or TNF-α was ~2 fold (mean 46318 vs 22679, P = 0.0006), ~5 fold (38928 vs 7712, P = 0.0006) and 
~3 fold (39007 vs 12738, P = 0.0012) higher following rHRV-DNA than after 3X pVAX-Gag-Tat vaccination, 
respectively (Fig. 2A–C).
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The number of Gag-specificCD8+ T cells that concurrently produced at least 2 cytokines (poly-functional 
CD8+ T cells) following KdGag197–205 peptide stimulation was also determined. Vaccination with rHRV-DNA 
resulted in ~9-fold more cells producing IFN-γ and TNF-α than 3X pVAX-Gag-Tat vaccination (1259 vs 140, 
P = 0.0006) as shown in Fig. 2D. Similarly, the number of cells that produced IL-2 and TNF-α was ~6 fold higher 
in rHRV-DNA vaccinated mice (4240 vs 707, P = 0.0012) as shown in Fig. 2E, while the number of cells pro-
ducing IFN-γ and IL-2 was ~2.5 fold (1836 vs 523, P = 0.0041) higher (Fig. 2F). The number of triple cytokine- 
(IFN-γ , IL-2 and TNF-α ) producing CD8+ T cells was ~3.3 fold higher after rHRV-DNA vaccination (1398 vs 
427, P = 0.0070) as shown in Fig. 2G.
We then examined the number of CD8+ cells with an effector memory T cell (TEM) phenotype. Effector 
memory is vital to establish antigen-specific recall responses22,30 and is required for an effective HIV vaccine. 
As TEM are marked by CD44 expression31, we determined the number of CD44hiCD8+ T cells which synthesised 
cytokines after splenocytes were stimulated with the KdGag197–205 peptide.
The number of CD44hiCD8+ T cells that produced IFN-γ , TNF-α or IL-2 was 3–4 fold higher in the 
rHRV-DNA-than in the 3X pVAX-Gag-Tat vaccination group (Supplementary Fig. S1A–C). Although the num-
ber of double and triple positive CD44hiCD8+ T cells was modest after rHRV-DNA or 3X pVAX-Gag-Tat vaccina-
tion, it was significantly higher in the rHRV-DNA group (Supplementary Fig. S1D–G, respectively). In summary, 
Figure 1. rHRV-DNA vaccination elicits robust CMI in the spleen. Mice (n = 7) received either 2 doses 
(containing 5 × 106 TCID50 per dose per animal) of wild-type (wt)-HRV-A1 followed by 50 μ g pVAX 
(vaccination control group) or 2 doses of rHRV-Gag/Tat (containing 5 × 106 TCID50 per dose per animal) 
followed by a single ID dose of 50 μ g of a DNA cocktail (pVAX-Gag-Tat) containing equimolar concentrations 
of pVAX-sTat-IMX313 and pVAX-Gag-PRF. This vaccination regimen is referred to as rHRV-DNA prime-boost 
vaccination. Other mice were vaccinated with 3 ID doses (50 μ g/dose per animal) of pVAX-Gag-PRF/pVAX-
sTat-IMX313 and referred to as 3X pVAX-Gag-Tat vaccination. Splenocytes were collected 14 days after the 
final dose and restimulated in duplicate with overlapping peptides representing the entire Gag protein.  
(A) Gag peptide pool 1, (B) Gag peptide pool 2, (C) Gag peptide pool 3 and (D) Gag peptide pool 4 in an IFN-γ 
ELIspot. (E) Total Gag responses depicted in pools 1–4. (F) Tat-specific responses from cells stimulated with 
the complete Tat peptide pool. Splenocytes were also stained with the H-2Kd-Gag197–205 tetramer for 1 h at room 
temperature and the number of tetramer-positive CD8+ T cells was analyzed by flow cytometry (G). The data 
are representative of 2 independent experiments (n = 7) and are plotted as mean SFU per 106 splenocytes  
(± SEM). Each symbol represents an individual mouse. *p < 0.05, **p < 0.01 and ***p < 0.001 (Mann–Whitney 
U test).
www.nature.com/scientificreports/
4Scientific RepoRts | 6:36658 | DOI: 10.1038/srep36658
the data also illustrate that rHRV-DNA is more effective at inducing poly-functional Gag-specific CD8+ T cell 
responses in the spleen than wt-HRV-pVAX or 3X pVAX-Gag-Tat vaccination.
rHRV-DNA vaccination elicits superior poly-functional CMI in the gut mucosa. The vast majority 
of CD4+ T cell death during acute HIV-1 infection occurs in the gut and thus poly-functional CMI responses 
at the gut mucosa are likely to significantly reduce CD4+ T cell death32. Vaccination with wt-HRV-A1/pVAX 
failed to induce KdGag197–205-specific CD8+ T cell responses above background from unstimulated lympho-
cytes prepared from mesenteric lymph nodes, whereas high numbers of Gag-specific cells were readily detected 
following rHRV-DNA vaccination (Fig. 3A–G). Furthermore, the number of mono-functional (Fig. 3A–C) 
and poly-functional cells (Fig. 3D–G) generated after rHRV-DNA was significantly higher than that after 3X 
pVAX-Gag-Tat vaccination. The number of poly-functional TEM cells derived from the mesenteric lymph nodes 
produced following rHRV-DNA or 3X pVAX-Gag-Tat vaccination was generally modest, although rHRV-DNA 
appeared to be more effective than 3X pVAX-Gag-Tat (Supplementary Fig. S2). Overall, consistent with the sple-
nocyte data, rHRV-DNA induced poly-functional Gag-specific CD8+ T cell responses in the gut more effectively 
than wt-HRV-pVAX or 3X pVAX-Gag-Tat vaccination.
rHRV-DNA vaccination elicits superior Tat-specific humoral responses. High titre Tat-specific 
serum IgG appears to correlate with control of HIV infection in humans11,33 and SIV in macaques34,35. Therefore, 
we compared the titres of Tat-specific IgG generated after vaccination with wt-HRV-A1/pVAX, rHRV-DNA 
or 3X pVAX-Gag-Tat. Tat-specific IgG was detected in serum samples from all vaccinated mice (except in the 
wt-HRV-A1/pVAX group) with mean reciprocal endpoint titres ranging from 270 to 65610 in the rHRV-DNA 
vaccinated group and from 30 to 810 in the 3X pVAX-Gag-Tat vaccinated group (Fig. 4A). In the rHRV-DNA vac-
cinated group, anti-Tat IgG was detectable in samples after the first rHRV dose with a mean titre of 236, but was 
undetectable in the 3X pVAX-Gag-Tat vaccinated group at this time point. After the 2nd dose, the mean anti-Tat 
antibody titre in serum from the rHRV-DNA vaccinated group increased by ~65 fold (from 236 to 15312) and 
Figure 2. rHRV-DNA elicits superior systemic poly-functional CMI. Mice were vaccinated as described in 
the legend to Fig. 1 and splenocytes harvested 14 days after the final dose. The cells were stimulated for 1 h with 
5 μ g/ml of the H-2Kd-restricted Gag197–205 immuno-dominant peptide, in the presence of protein transport 
inhibitor (Brefeldin A, eBiosciences) for a further 6 h and cytokine production then analyzed by flow cytometry. 
We gated on CD8+ T cells to assess the number of CD8+ T cells producing (A) IFN-γ , (B) TNF-α , (C) IL-2,  
(D) IFN-γ and TNF-α , (E) TNF-α and IL-2, (F) IFN-γ and IL-2 and (G) IFN-γ , TNF-α and IL-2 after stimulation. 
The data are representative of 2 independent experiments, plotted as mean (n = 7) ± SEM and each symbol 
represents an individual mouse. *p < 0.05, **p < 0.01, ***p < 0.001 and ns, p > 0.05 (Mann–Whitney U test).
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was considerably higher than that in serum from the 3X pVAX-Gag-Tat group (mean titer = 9). Administration 
of a single DNA booster dose increased the IgG titres by ~1.2 fold (from 15312 to 17704) in the rHRV-DNA group 
and by ~38 fold (from 9 to 338) in the 3X pVAX-Gag-Tat vaccinated group. The differences in serum IgG titres 
were statistically significant at each time point between the two vaccinated groups (Fig. 4A). The OD generated 
by serum from wt-HRV/pVAX vaccinated animals was lower than the cut-off, thus the antibody titre in this vac-
cination group was considered to be zero.
We also examined CVL samples from vaccinated animals for Tat-specific mucosal sIgA, as the presence of 
antigen-specific sIgA in blood or at the mucosa appears to correlate with protection in humans36,37. We detected 
modest levels of sIgA (mean titre 20) in CVL samples collected after the DNA boost from all mice in the 
rHRV-DNA group, but not from mice in the wt-HRV/pVAX or 3X pVAX-Gag-Tat vaccinated group (Fig. 4B). 
Most surprisingly, sIgA was not detected in samples prior to the DNA boost, indicating that this was required for 
the rHRV-Gag/Tat vaccine to induce detectable mucosal sIgA. On the whole, the results described above indicate 
that rHRV-DNA is more effective at inducing robust Gag and Tat-specific CMI as well as Tat-specific humoral 
immune responses at the mucosa than wt-HRV-pVAX or 3X pVAX-Gag-Tat vaccination.
rHRV-DNA controls the EcoHIV viral load post-challenge. EcoHIV is a murine HIV challenge model 
and has been used previously to evaluate the efficacy of candidate HIV vaccines24,38. However, there is no docu-
mented evidence that EcoHIV can infect mice via the intravaginal route which accounts for a majority of HIV 
transmissions6, and thus the IP route is a convenient route to successfully deliver the virus24,38. EcoHIV encodes 
the complete range of HIV proteins, including Tat, from the HIV-1 Clade B NL4-3 strain, except for the HIV 
gp120 which was replaced with gp80 from the murine leukaemia virus39. The virus spreads from the primary site 
of infection to the spleen and the brain in a manner reminiscent of HIV infection39.
Consequently, we examined the protective efficacy of wt-HRV/pVAX, rHRV-DNA or 3X pVAX-Gag-Tat vac-
cination against EcoHIV challenge. All animals were challenged 10 days after the final vaccination, then culled 7 
Figure 3. rHRV-DNA vaccination elicits superior poly-functional CMI in the gut mucosa. Mice were 
vaccinated as described in the legend to Fig. 1 and lymphocytes prepared from mesenteric lymph nodes 
harvested 14 days after the final dose. The lymphocytes were stimulated for 1 h with 5 μ g/ml of the H-2Kd-
restricted Gag197–205 immuno-dominant peptide and then cultured in the presence of Brefeldin A for a further 
6 h. Cytokine production was analyzed by flow cytometry. We gated on CD8+ T cells to assess the number of 
CD8+ T cells producing (A) IFN-γ , (B) TNF-α , (C) IL-2, (D) IFN-γ and TNF-α , (E) TNF-α and IL-2, (F) IFN-γ 
and IL-2 and (G) IFN-γ , TNF-α and IL-2 after stimulation. The data are representative of 2 independent 
experiments, plotted as mean (n = 7) ± SEM and each symbol represents an individual mouse. *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001 (Mann–Whitney U test).
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days later and splenocytes, PECs and peripheral blood samples collected to quantify the viral load (VL) by qRT 
PCR. The results were normalised to the RPL13a house-keeping gene as described previously24,38. Vaccination 
with rHRV-DNA or 3X pVAX-Gag-Tat significantly reduced the EcoHIV VL by ~204 fold (p = 0.0006) and ~8 
fold (p = 0.0006) in PECs (Fig. 5A), ~62 fold (p = 0.0006) and ~11 fold (p = 0.0006) in splenocytes (Fig. 5B), and 
by ~40 fold (p = 0.0006) and ~7.5 (p = 0.0006) in blood (Fig. 5C), respectively, compared to vaccination with 
wt-HRV/pVAX. Furthermore, rHRV-DNA vaccination showed superior control of EcoHIV infection compared 
to 3X pVAX-Gag-Tat vaccination and reduced the VL by ~25 fold (p = 0.0006) in PECs, ~5.5 fold (p = 0.0286) in 
splenocytes and by ~5.4 fold (p = 0.0035) in peripheral blood as shown in Fig. 5A–C. Taken together, the data sug-
gest that the rHRV-DNA regimen can also be used to achieve effective virologic control of EcoHIV-1 infection.
Discussion
In this study, we report that a vaccination regimen comprised of a cocktail of replication-competent rHRVs encod-
ing HIV Gag and Tat (rHRV-Gag/Tat) followed by a DNA vaccine encoding the same proteins (pVAX-Gag-Tat), 
elicited robust Gag-specific CMI in the spleen and gut mucosa, and high titer anti-Tat serum IgG and sIgA in 
the vagina of vaccinated mice. Furthermore, the vaccine-elicited immune responses controlled infection in a 
mouse EcoHIV challenge model. Intranasal (IN) vaccination generates pan-mucosal and systemic immunity 
as described previously8 and our data provide new support to consider IN vaccination as a method to induce 
anti-HIV immunity at the mucosa and systemically. It is not possible to directly compare the immunogenicity 
and efficacy of rHRV-Gag/Tat vaccination to that reported previously by Crotty et al. using the recombinant Sabin 
poliovirus-based HIV vaccines in macaques due to differences in animal models and challenge viruses used17. 
However, our data confirm that, similar to Sabin poliovirus-based vaccines, IN administration of the rHRV-Gag/Tat 
vaccine in a heterologous prime-boost strategy (rHRV-DNA) elicited systemic and mucosal HIV-specific 
immune responses that significantly controlled EcoHIV infection.
Heterologous prime-boost vaccination has been shown to generate superior CMI and humoral immunity 
compared with homologous prime-boost vaccination40. Similarly, our data showed that the rHRV-DNA regimen 
elicited poly-functional Gag-specific CD8+ T cells more effectively than wtHRV-A1/pVax or 3X pVAX-Gag-Tat 
vaccination at the mucosa (Fig. 3 and Supplementary Fig. S2) and systemically (Figs 1 and 2 and Supplementary 
Fig. S1). The appearance of high quality Gag- and Tat-specific CMI responses appears to correlate with long-term 
HIV control in humans12,13 and SIV in non-human primates22,41,42, thus our data suggest that the rHRV-DNA 
regimen might control SIV when tested in macaques or HIV-1 infections in humans. In addition to robust 
CMI, rHRV-DNA induced higher Tat-specific serum IgG and mucosal sIgA titres than wtHRV-A1/pVax or 
3X pVAX-Gag-Tat vaccination (Fig. 4A), additional markers which appear to correlate with control of HIV in 
humans11,33 and SIV in animals34,43. Although we did not assess functionality of the Tat-specific antibodies in 
terms of anti-Tat neutralization, a previous study conducted in our laboratory indicated that intradermal vacci-
nation with pVAX-sTat-IMX313, one of the vaccines used in the regimens of this study, elicited antibodies with 
Tat neutralization activity that correlated with control of EcoHIV25. Surprisingly, Tat-specific sIgA was detected 
in CVL samples from rHRV-DNA vaccinated animals only after the DNA boost (Fig. 4B). The reason for this 
Figure 4. rHRV-DNA vaccination elicits superior Tat-specific humoral responses. Mice were vaccinated 
as described in the legend to Fig. 1. Blood and CVL samples were collected 1 day before each vaccination 
and 14 days after the final dose. (A) ELISA results showing serum log10 anti-Tat IgG titres. (B) ELISA results 
showing anti-Tat sIgA titres. Data are plotted as mean (n = 7) ± SEM and are representative of 2 independent 
experiments. *p ≤ 0.05 and ***p ≤ 0.001 (Mann–Whitney U test).
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unexpected result remains unclear. However, sIgA was not detected in any animals vaccinated 3X pVAX-Gag-Tat 
at any time point; this was not surprising as we have previously shown that a minimum of 5 doses is required for 
a Tat DNA vaccine to elicit detectable mucosal sIgA25.
Although other studies generally administer recombinant viruses as a boost following a DNA prime40,44,45, our 
results are consistent with studies which have shown that administering a recombinant virus followed by a DNA40 
or protein vaccine46 in a heterologous prime-boost vaccination strategy elicits high titre immune responses. 
Moreover, a boost with a DNA vaccine following rHRV-Gag/Tat prime is likely to elicit robust HIV-specific 
immune responses at the mucosa and systemically in vaccinated humans. Regular boosting with DNA may also 
be feasible and offers the advantage that anti-vector responses will not accumulate over time and prevent further 
boosting, as would be the case for a recombinant virus-based vaccine.
Tat shows potent adjuvanticity through its ability to dimerize and promote maturation and activation of 
monocyte-derived dendritic cells47, to generate and present sub-dominant MHC-1 epitopes by modifying the 
proteolytic activity of the immunoproteosome48, and induce high levels of surface MHC-1 peptide expression. 
Although we did not directly investigate the effect of including Tat in the rHRV-DNA vaccination regimen, based 
on this body of evidence, we speculate that Tat enhanced and broadened the overall Gag-specific T cell responses 
in addition to inducing Tat specific responses. To further support our hypothesis, Gavioli et al. demonstrated 
previously that including Tat in a multi-antigenic vaccine enhanced the magnitude and broadened Gag- and 
Env-specific T cell responses without affecting the quality of the Th2 responses27. Furthermore, the inclusion of 
Tat in a candidate vaccine against Herpes Simplex Virus type 1 (HSV-1) enhanced the induction of broad, high 
magnitude effector memory HSV-1 specific CD 8 T cell responses49 that completely protected mice after a lethal 
intravaginal challenge with wild type HSV-149,50 HSV-1. Collectively, this evidence supports the inclusion of Tat 
as a component of a multi antigenic vaccine and implies that the rHRV-DNA vaccination regimen reported here, 
that contains Tat and Gag as immunogens, will most likely be highly immunogenic.
As robust immune responses do not necessarily indicate protection against virus challenge51,52, we evaluated 
the efficacy of rHRV-DNA vaccination using a murine HIV challenge model, EcoHIV39. The rHRV-DNA regi-
men resulted in effective control of the EcoHIV infection (Fig. 5A,B). However, it is unclear if humoral immunity 
and/or CMI were responsible for this control and additional experiments will be necessary to address this issue. 
Nevertheless, the robust Gag-specific CMI and high titer anti-Tat responses are thought to offer protective bene-
fits against HIV in long-term non-progressors11,12 and non-human primates23,34, and thus it is possible that both 
Gag-CMI and anti-Tat responses contributed.
Figure 5. rHRV-DNA vaccination controls EcoHIV viral load post-challenge. Mice were vaccinated with 
rHRV-DNA, wt-HRV- pVAX or 3X pVAX-Gag-Tat at 2 week intervals and then challenged with 1.5 μ g p24 of 
EcoHIV/NL4-3 10 days post final vaccination. The viral load in PECs, splenocytes and blood was determined 
by qRT-PCR; EcoHIV RNA levels in (A) PECs, (B) splenocytes and (C) blood 7 days post challenge. EcoHIV 
mRNA levels were normalised to RPL13a mRNA and the data represent the mean (n = 7) ± SEM. *p ≤ 0.05, 
**p ≤ 0.01 and ***p ≤ 0.001 (Mann–Whitney U test).
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In conclusion, we demonstrate for the first time that a live recombinant HRV vaccine encoding HIV proteins 
when administered in a heterologous vaccination regimen involving priming with virus followed by a single DNA 
boost is highly immunogenic in mice and that the vaccine-induced immune responses control EcoHIV infection 
post challenge. The data presented in this study have important ramifications for the development of effective 
mucosal HIV-1 vaccines in the future.
Methods
Recombinant HRV-Gag/Tat production and purification. We have previously described the produc-
tion of rHRV-Gag/Tat21. Briefly, five overlapping fragments representing the full length HIV gag or the tat gene 
were individually inserted into the P1/P2 junction in a replication-competent HRV A1 cDNA53 to generate 5 
rHRVs each encoding a discrete, overlapping fragment of the Gag protein and one rHRV encoding the full length 
Tat protein. Each recombinant virus was produced by transfecting H1-Hela cells with in vitro transcribed viral RNA 
generated with the TransIT® -mRNA transfection kit (Mirus) following the manufacturer’s instructions. The indi-
vidual rHRVs were purified and titrated as described previously21 then combined into a cocktail (rHRV-Gag/Tat) 
and re-titrated to ensure that the vaccination dose contained a uniform virus concentration.
DNA vaccines. Plasmids encoding HIV Gag and perforin (PRF) (pVAX-Gag-PRF) or HIV Tat fused to 
the oligomerisation domain of the C4b-p (pVAX-sTat-IMX313) have been described recently24,25. Briefly, the 
HIV gag and PRF genes were inserted downstream of the CMV and SV40 promoters, respectively, to generate 
pVAX-Gag-PRF24. To generate pVAX-sTat-IMX313, the human tissue plasminogen activator leader sequence 
and the oligomerisation domain of C4b-p (IMX313) were introduced at the N- and C-termini respectively of the 
HIV tat gene25.
Animals and immunisations. Female 6–8 week old BALB/c mice were obtained from the University of 
Adelaide Laboratory Animal Services and maintained under PC2 conditions in individually ventilated cages 
fitted with a HEPA filter. All experimental animal protocols were approved by the Women’s and Children’s Health 
Network (project licence number AE783-02-2012 ), the South Australia Pathology Animal Ethics committee 
(project licence number 29-15) and the University of Adelaide Animal Ethics Committee (project licence num-
ber M-2012-201) under the regulations and guidelines of “Australian Code of Practice for the Care and Use 
of Animals for Scientific Purposes” issued by the Australian National Health and Medical Research Council 
(NHMRC). Vaccinations were performed at two week intervals via the IN route after 2% isofluorane anaesthesia 
for the rHRV-Gag/Tat cocktail andwild-type (wt)-HRV-A1 as described54 or via the intradermal (ID) route for 
the DNA vaccines as described24. We have used intradermal vaccination for DNA vaccines for some time because 
this route has a higher frequency of dendritic cells (DC) and other antigen presenting cells than the intramuscular 
route55,56. As the efficacy of vaccination is dependent on uptake, processing and presentation of the immunogen 
by DC, then we and others believe that this route is more effective.
Mice (n = 7) received either 2 doses (containing 5 × 106 TCID50 per dose per animal) of wt-HRV-A1 fol-
lowed by 50 μ g pVAX (vaccination control group, referred to hereafter as wt-HRV-A1/pVax) or 2 doses of 
the rHRV-Gag/Tat cocktail (containing 5 × 106 TCID50 per dose per animal) followed by a single ID dose of 
50 μ g of a DNA cocktail (pVAX-Gag-Tat), containing equimolar concentrations of pVAX-sTat-IMX313 and 
pVAX-Gag-PRF. The latter will be referred to hereafter as rHRV-DNA prime-boost vaccination. Another group of 
mice received 3 ID doses (50 μ g of a DNA cocktail per dose) of pVAX-Gag-Tat and this homologous prime-boost 
vaccination strategy will be referred to hereafter as 3X pVAX-Gag-Tat vaccination. Blood and cervical vaginal lav-
age (CVL) samples were collected one day prior to each vaccination and 14 days after the final vaccination, when 
the mice were euthanized, and examined for anti-Tat antibody responses. Splenocytes and lymphocytes from the 
mesenteric lymph nodes (mesenteric lymphocytes) were also harvested at this time point for analysis of CMI.
Enzyme-linked immunosorbent spot assay (ELISpot). ELISpots were performed to determine 
the breadth and magnitude of HIV-specific CMI in splenocytes from vaccinated mice. A panel of 15–19 mer 
overlapping peptide pools spanning the entire Gag and Tat proteins was obtained from the NIH AIDS reagent 
bank (Germantown, MD, USA). Mouse interferon (IFN)-γ ELISpot was performed on RBC-depleted spleno-
cytes that were re-stimulated for 36 h with 4 μ g/ml of 5 Gag peptide pools or a Tat peptide pool as we described 
previously24,38. Briefly, multiscreen-IP HTS plates (Millipore) were coated with anti-mouse IFNγ (clone AN18, 
MabTech) and secreted IFNγ detected with anti-mouse IFNγ -biotin (clone R4-6A2, MabTech). Developed spots 
were counted automatically using an ELISpot reader (AID GmbH, Germany). The number of spots (spot forming 
units-SFUs) in unstimulated splenocytes was subtracted from the number in peptide-stimulated cells to generate 
the net Gag or Tat response.
Intracellular cytokine staining (ICS) and flow cytometry. Multi-colour ICS was performed on 
RBC-depleted splenocytes and mesenteric lymphocytes to determine IFN-γ , interleukin (IL)-2, and tumor necro-
sis factor (TNF)-α production from Gag-specific CD8+ T cells as described previously24,38. Briefly, the cells were 
stimulated for 1 h with 5 μ g/ml of the H-2Kd-restricted Gag197–205 (AMQMLKETI) immunodominant peptide57 
(China peptides, China) then cultured in the presence of protein transport inhibitor (Brefeldin A, eBiosciences) 
for a further 6 h. Staining was performed using fluorescence-activated cell sorting (FACS) Cytofix/Cytoperm 
buffer (BD Biosciences) with antibodies specific to mouse antigens CD8α (allophycocyanin (APC)-efluor780 
conjugated), CD44α (APC conjugated), IL-2 (peridinin chlorophyll 5.5 conjugated), IFN-γ (fluorescein isothi-
ocyanate (FITC) conjugated) and TNF-α (phycoerythrinconjugated) (BD Biosciences). The cells were analysed 
on a BD FACS Cantoand the results analysed with FlowJo X.0.7 software (Ashland, OR) using the gating strategy 
shown in Supplementary Figs S3–S6. The number of cells producing cytokines without prior stimulation was 
subtracted from the number in peptide-stimulated cells to generate the net Gag response.
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H-2Kd- Gag197–205 tetramer and antibody staining. RBC-depleted splenocytes were initially stained 
with the APC-conjugated H-2Kd-restricted Gag197–205 (AMQMLKETI) immunodominant peptide tetramer 
(Biomolecular Resource Facility, John Curtin School of Medical Research, Australian National University, 
Canberra, Australia) for 1 h at room temperature, washed twice in phosphate-buffered saline (PBS) and then 
re-stained with FITC-conjugated anti-mouse CD8α antibody (BD Biosciences). The cells were analysed 
on a BD FACS Canto and the results analysed with FlowJo X.0.7 software using the gating strategy shown in 
Supplementary Fig. S7. The number of unstained tetramer positive cells was subtracted from the number in 
tetramer-stained cells to generate the net tetramer positive cells.
Enzyme-linked immunosorbent assay (ELISA). Serum and CVL samples from mice were analyzed 
for anti-Tat antibodies by indirect ELISA as we described previously25. Briefly, Maxisorp plates (Corning 
Sigma-Aldrich) were coated with 500 ng of purified Tat protein in carbonate-bicarbonate buffer, blocked with 2% 
w/v bovine serum albumin (BSA) in PBS and then serial dilutions of serum and CVL samples added. Bound anti-
bodies were detected using horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin (Ig)G 
(GE Healthcare Life Sciences, USA) or anti-mouse IgA (Life Technologies) and the optical density (OD) read 
at 492 nm. Endpoint titres were determined as the reciprocal of the highest serum or CVL sample dilution with 
an OD reading above the cut-off, set as twice the standard deviation (SD) above the mean OD of serum samples 
from naïve mice.
EcoHIV/NL4-3 challenge. EcoHIV preparation, titration and challenge have been described previ-
ously24,38,39. Vaccinated mice were challenged via the intra-peritoneal (IP) route with EcoHIV equivalent to 1.5 μ g 
p24, then spleen, blood and peritoneal exudate cells (PECs) collected 7 days post challenge and examined by 
qRT-PCR as described previously24,58. Results were normalised to RPL13a mRNA levels after examining primer 
efficiency using the Δ Δ CT (threshold cycle) quantification method59.
Statistical analysis. Data presented as mean ± standard error of the mean (SEM) were generated with 
GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA). Non-parametric Kruskal-Wallis test was 
used to compare the difference between multiple vaccine groups. If this showed significant differences, then 
the Mann-Whitney U test was performed to compare differences between each vaccine group, independently. 
Statistical significance was determined using the Mann-Whitney U test; p < 0.05 was considered significant and 
p > 0.05 was considered non-significant.
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